Account wins from the 04/10/07 news brief

Share this article:
Wunderman has been selected to launch a consumer campaign for AstraZeneca's Faslodex, a medication that has been approved for use in postmenopausal women with hormone-receptor positive metastatic breast cancer that has progressed following therapy with a hormonal treatment like tamoxifen. Wunderman will handle DTC and DTP relationship marketing efforts aimed at raising awareness in late stage breast cancer patients. A print campaign is slated for summer 2007. In addition to Faslodex, Wunderman currently handles Arimidex and Casodex/Zoladex. All are part of AstraZeneca's oncology catalog.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.